Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06575075 · ClinicalTrials.gov registry record · Phase 1

Pilot Study of RR-HNK in OCD

A Phase 1 study of Obsessive - Compulsive Disorder, sponsored by Carolyn Rodriguez.

Recruiting
Registry status
Phase 1
Development phase
45
Enrollment target
1
Study location

NCT06575075: Recruiting Phase 1 study of Obsessive - Compulsive Disorder, sponsored by Carolyn Rodriguez.

NCT06575075 is a Phase 1 study of Obsessive - Compulsive Disorder that is actively recruiting participants, run by Carolyn Rodriguez. The registered enrollment target is 45 participants, below the 2,064-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06575075, a Phase 1 study of Obsessive - Compulsive Disorder, is actively recruiting participants, sponsored by Carolyn Rodriguez.

RECRUITING
Registry status
Phase 1
Development phase
45 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to understand how RR-HNK works in the brain to bring about a reduction in OCD symptoms.

Primary Outcome

Change in OCD severity is measured by the YBOCS (Yale Brown Obsessive-Compulsive Scale), a gold standard measure of obsessions and compulsions. For the YBOCS the minimum units are 0 and Maximum units on the total scale are 40. The higher the number on the YBOCS, the more severe the symptoms. Response is defined as at least a 35% reduction on the YBOCS.

Conditions Studied

Obsessive - Compulsive Disorder

Interventions

  • DRUG Placebo
  • DRUG RR-HNK/Hydroxynorketamine

Study Locations (1)

California

  • Stanford University School of Medicine - Palo Alto

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2026-01-23
Est. Completion 2029-11-30
Phase Phase 1
Carolyn Rodriguez

2 total trials

What NCT06575075 shows while recruiting

NCT06575075 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 2,064-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Obsessive - Compulsive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06575075 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT06575075 about?

NCT06575075 is a clinical study titled "Pilot Study of RR-HNK in OCD". The purpose of this study is to understand how RR-HNK works in the brain to bring about a reduction in OCD symptoms.

What is the current status of trial NCT06575075?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2026-01-23. Estimated completion is 2029-11-30.

What conditions does trial NCT06575075 study?

This clinical trial studies the following conditions: Obsessive - Compulsive Disorder.

What interventions are being tested in trial NCT06575075?

The interventions under investigation include: Placebo (DRUG), RR-HNK/Hydroxynorketamine (DRUG).

Who is sponsoring clinical trial NCT06575075?

This trial is sponsored by Carolyn Rodriguez, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06575075 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obsessive - Compulsive Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06575075's enrollment target sits among peer trials

45 47th of 84 higher than 36 of 84 other Obsessive - Compulsive Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Obsessive - Compulsive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00804154 · 45 participants · Phase 1

    Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer

  • NCT01851694 · 45 participants · NA

    Beta-cell Response to Incretin Hormones in Cystic Fibrosis

  • NCT02896335 · 45 participants · Phase 2

    Palbociclib and Pembrolizumab In Central Nervous System Metastases

  • NCT03454035 · 45 participants · Phase 1

    Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06575075

Source: ClinicalTrials.gov NCT06575075, the US trial registry maintained by the National Library of Medicine. NCT06575075 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.